Study of A3309 in Patients With Dyslipidemia

Albireo

Status and phase: Completed; Phase 2

Conditions: Dyslipidemia

Treatments: Drug: A3309; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT01069783

A3309-005

Details and patient eligibility

About

The purpose of this trial is to determine the efficacy and safety of A3309 administered to patients with dyslipidemia (high cholesterol levels).

Enrollment: 36 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients meet protocol specified criteria for dyslipidemia and has successfully completed study requirements with no clinically relevant findings

Exclusion criteria

• Medical history or medical condition that would not make the patient a good candidate for the study or would limit the patient´s capability to complete the study

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

36 participants in 3 patient groups, including a placebo group

A3309 low dose

Experimental group

Treatment:

Drug: A3309

Drug: A3309

A3309 high dose

Experimental group

Treatment:

Drug: A3309

Drug: A3309

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo